Orient Bio

Orient Bio Equity Growth

The Year-over-Year Equity Growth of Orient Bio (002630.KS) as of Nov 4, 2026 is -4.60 %. In the previous year, Year-over-Year Equity Growth was -15.57 % — a change of -70.47% (higher).

Equity Growth

-4.60 %

YoY

-70.47%

Last updated:

Year-over-Year Equity Growth of Orient Bio is 2026 -4.60 % . Year-over-Year Equity Growth of Orient Bio was 2025 -15.57 % . It decreases by -70.47% higher compared to the previous year.

The Orient Bio Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2019
22.88 KRW
Jan 1, 2020
-19.79 KRW
Jan 1, 2021
-6.58 KRW
Jan 1, 2022
71.36 KRW
Jan 1, 2023
-14.18 KRW
Jan 1, 2024
19.19 KRW
Jan 1, 2025
-15.57 KRW
Jan 1, 2026
-4.60 KRW
The Orient Bio Equity Growth history
YEAREquity GrowthYoY
-4.60 %-70.47%
-15.57 %-181.11%
19.19 %-235.37%
-14.18 %-119.87%
71.36 %-1,184.94%
-6.58 %-66.77%
-19.79 %-186.51%
22.88 %-191.51%
-25.00 %+193.21%
-8.53 %-119.80%
43.07 %-1,936.88%
-2.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orient Bio Stock analysis

What does Orient Bio do? Orient Bio Inc generates revenue through the production and supply of laboratory animals such as mice, rats, guinea pigs, hamsters, SPF rabbits, and beagles. The company also offers CRO services including safety assessments and new drug development, alongside medical and library equipment like barrier systems. Additional income comes from support services such as rodent surgery, laboratory diagnostics, transgenic services, and genetic testing. The firm further provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines through its subsidiaries. Orient Bio Inc's primary customers include research institutions, pharmaceutical companies, and medical facilities requiring laboratory animals and specialized services. The company's product segments consist of live animals, CRO services, medical equipment, and ancillary products like feeds and reagents. Subsidiaries contribute to revenue by supplying complementary items such as disinfectants and power supply equipment. The business model leverages a diversified portfolio of biotechnology products and services, targeting both direct research and development needs and ancillary support requirements. Revenue streams are derived from the sale of animals, provision of CRO services, equipment sales, and subsidiary product lines, ensuring steady income across multiple segments. Orient Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Orient Bio stock

Year-over-Year Equity Growth of Orient Bio is -4.60 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Orient Bio since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Orient Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Orient Bio

All Key Metrics — Orient Bio